BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 2464794)

  • 21. Safety and efficacy of subcutaneous Campath-1H for treating residual disease in patients with chronic lymphocytic leukemia responding to fludarabine.
    Montillo M; Cafro AM; Tedeschi A; Brando B; Oreste P; Veronese S; Rossi V; Cairoli R; Pungolino E; Morra E
    Haematologica; 2002 Jul; 87(7):695-700; discussion 700. PubMed ID: 12091119
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Phase II clinical study of SH L 573 (fludarabine phosphate) in patients with chronic lymphocytic leukemia].
    Miyawaki S; Imamura M; Kobayashi S; Ohnishi K; Hodohara K; Mizoguchi H; Tomonaga M; Tango T; Ohno R
    Rinsho Ketsueki; 1999 Dec; 40(12):1236-44. PubMed ID: 10658476
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A phase II study of DT fusion protein denileukin diftitox in patients with fludarabine-refractory chronic lymphocytic leukemia.
    Frankel AE; Fleming DR; Hall PD; Powell BL; Black JH; Leftwich C; Gartenhaus R
    Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3555-61. PubMed ID: 14506141
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fludarabine, cyclophosphamide, and mitoxantrone as initial therapy of chronic lymphocytic leukemia: high response rate and disease eradication.
    Bosch F; Ferrer A; Villamor N; González M; Briones J; González-Barca E; Abella E; Gardella S; Escoda L; Pérez-Ceballos E; Asensi A; Sayas MJ; Font L; Altés A; Muntañola A; Bertazzoni P; Rozman M; Aymerich M; Giné E; Montserrat E
    Clin Cancer Res; 2008 Jan; 14(1):155-61. PubMed ID: 18172266
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A 3-day schedule of fludarabine in previously treated chronic lymphocytic leukemia.
    Robertson LE; O'Brien S; Kantarjian H; Koller C; Beran M; Andreeff M; Lerner S; Plunkett W; Keating MJ
    Leukemia; 1995 Sep; 9(9):1444-9. PubMed ID: 7658710
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Low-dose fludarabine and cyclophosphamide in elderly patients with B-cell chronic lymphocytic leukemia refractory to conventional therapy.
    Marotta G; Bigazzi C; Lenoci M; Tozzi M; Bocchia M; Lauria F
    Haematologica; 2000 Dec; 85(12):1268-70. PubMed ID: 11114133
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Activity of oral fludarabine phosphate in previously treated chronic lymphocytic leukemia.
    Boogaerts MA; Van Hoof A; Catovsky D; Kovacs M; Montillo M; Zinzani PL; Binet JL; Feremans W; Marcus R; Bosch F; Verhoef G; Klein M
    J Clin Oncol; 2001 Nov; 19(22):4252-8. PubMed ID: 11709569
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of advanced chronic lymphocytic leukemia by fludarabine. Results of a clinical phase-II study.
    Hiddemann W; Rottmann R; Wörmann B; Thiel A; Essink M; Ottensmeier C; Freund M; Büchner T; van de Loo J
    Ann Hematol; 1991 Jul; 63(1):1-4. PubMed ID: 1715191
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of fludarabine, cyclophosphamide/doxorubicin/prednisone, and cyclophosphamide/doxorubicin/vincristine/prednisone in advanced forms of chronic lymphocytic leukemia: preliminary results of a controlled clinical trial. The French Cooperative Group on Chronic Lymphocytic Leukemia.
    Semin Oncol; 1993 Oct; 20(5 Suppl 7):21-3. PubMed ID: 8235691
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Phase I clinical study of SH L573 (fludarabine phosphate) in patients with chronic lymphocytic leukemia and adult T-cell leukemia/lymphoma].
    Arima N; Mizoguchi H; Shirakawa S; Tomonaga M; Takatsuki K; Ohno R
    Gan To Kagaku Ryoho; 1999 Apr; 26(5):619-29. PubMed ID: 10234292
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pulmonary toxicity associated with fludarabine monophosphate.
    Hurst PG; Habib MP; Garewal H; Bluestein M; Paquin M; Greenberg BR
    Invest New Drugs; 1987; 5(2):207-10. PubMed ID: 2443463
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intense reversal of bone marrow angiogenesis after sequential fludarabine-induction and alemtuzumab-consolidation therapy in advanced chronic lymphocytic leukemia.
    Molica S; Montillo M; Ribatti D; Mirabelli R; Tedeschi A; Ricci F; Veronese S; Vacca A; Morra E
    Haematologica; 2007 Oct; 92(10):1367-74. PubMed ID: 17768114
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia.
    Keating MJ; O'Brien S; Albitar M; Lerner S; Plunkett W; Giles F; Andreeff M; Cortes J; Faderl S; Thomas D; Koller C; Wierda W; Detry MA; Lynn A; Kantarjian H
    J Clin Oncol; 2005 Jun; 23(18):4079-88. PubMed ID: 15767648
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fludarabine phosphate in chronic lymphoproliferative diseases. The French Group on CLL.
    Binet JL
    Nouv Rev Fr Hematol (1978); 1993 Feb; 35(1):5-7. PubMed ID: 7685518
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fludarabine phosphate: a synthetic purine antimetabolite with significant activity against lymphoid malignancies.
    Chun HG; Leyland-Jones B; Cheson BD
    J Clin Oncol; 1991 Jan; 9(1):175-88. PubMed ID: 1702143
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of refractory chronic lymphocytic leukemia with fludarabine phosphate via the group C protocol mechanism of the National Cancer Institute: five-year follow-up report.
    Sorensen JM; Vena DA; Fallavollita A; Chun HG; Cheson BD
    J Clin Oncol; 1997 Feb; 15(2):458-65. PubMed ID: 9053466
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic significance of lymphocyte morphology in patients with advanced chronic lymphocytic leukemia treated with first line therapy of fludarabine + prednisone.
    Mauro FR; Gentile M; Mancini F; Giannarelli D; Guarini A; De Propriis MS; Cerretti R; Foa R
    Haematologica; 2002 Jun; 87(6):602-8. PubMed ID: 12031916
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Fludarabine treatment of chronic lymphoid leukemia].
    Gabeeva NG; Pivnik AV; Moiseeva TN; Zybunova EE; Samoĭlova RS; Kremenetskaia AM; Varlamova EIu; Kaplanskaia IB
    Ter Arkh; 2000; 72(8):42-5. PubMed ID: 11019427
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical experience with fludarabine and its immunosuppressive effects in pretreated chronic lymphocytic leukemias and low-grade lymphomas.
    Fenchel K; Bergmann L; Wijermans P; Engert A; Pralle H; Mitrou PS; Diehl V; Hoelzer D
    Leuk Lymphoma; 1995 Aug; 18(5-6):485-92. PubMed ID: 8528057
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Concomitant administration of chlorambucil limits dose intensity of fludarabine in previously treated patients with chronic lymphocytic leukemia.
    Weiss M; Spiess T; Berman E; Kempin S
    Leukemia; 1994 Aug; 8(8):1290-3. PubMed ID: 8057664
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.